Fri, Jul 25, 2014, 2:42 PM EDT - U.S. Markets close in 1 hr 18 mins

Recent

% | $
Click the to save as a favorite.

Pressure BioSciences, Inc. Message Board

mgs1066 8 posts  |  Last Activity: May 14, 2014 10:53 AM Member since: Feb 15, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Start buying back shares. Pay off the debt and do buy backs. They've done the job. They're there. Time for the big rewards. It's Miller Time!

    They'll probably not do that but that's what I think they should do. What are they gonna do, buy more chickens? They could. Merge with the egg company - um what's its name?? Buy pork? Why buy a less efficient meat? Buy beef, that's an even less efficient meat. Buy Chick Fillet? - vertically integrate? Just buy the stock!

    Sentiment: Hold

  • mgs1066 mgs1066 May 12, 2014 6:32 PM Flag

    Quick follow up to clarify - When administered via IV. I'm saying that when administered via IV it is not behaving as they expected. I know in the rat model they did testing to determine where exactly the multistem cells were going.

    For RTI, that is not via IV, correct? It is probably working well because it is not via IV.

    I remember recently reading about an oncology company that reported that their new drug had shown amazing efficacy against a particular type of cancer cell! - but that was in a test tube. And someone posted a response to that posting that well - that's fine in a test tube but that kind of drug would never reach that kind of cancer cell in a human body. Can't recall the details but it was in the past month I recall I read those postings.

    So - going back to Multistem - either they got the good stuff but it did got lost on its journey or - they didn't get the good stuff - or, maybe, it's just not the real deal, but then what does RTI have?

    Sentiment: Sell

  • It is a problem. I suspect the Multistem cells are either being sequestered in some organ - lungs? liver? and eventually expelled, or just being expelled - urinated, too quickly. If you make the assumption that the efficacy is really for real - and RTI Surgical is using the product so either they are marketing a fake product to the medical community or Multistem is working for RTI. And I believe RTI has been complimentary about the Multistem product. Then the efficacy is there - then the conclusion is the product did not behave as expected in the human body. Multistem in humans - it is basically in its native environment - not in a rat or in a rabbit, so maybe it would behave differently.

    So, looking at the OSIRs product and the partial success OSIRs was having - I say partial because it isn't all that great, oddly, it looks like ATHX just rushed through an abbreviated phase I to confirm tolerability and - doing a real phase 1 that looked for some level of efficacy would have required months more time.

    So yah, I'm out. Maybe stroke is good. I'll find out from the sidelines. I bought MU. Slow and steady to the party, I hope.

    Sentiment: Sell

  • they release the results from the phase I test. Good or bad, I can't think of a reason not to have it out already.

  • back to AHRO. Check Yahoo symbol AHROD.

  • 10 trading days. Right?

  • A lot of debt is going to get paid off shortly.

    Sentiment: Strong Buy

  • Reply to

    I went into this eyes wide open

    by ohmtaxi Apr 28, 2014 10:57 AM
    mgs1066 mgs1066 Apr 28, 2014 11:19 AM Flag

    I spent a lot of time researching this. Reading documents at ncbi. And the one guy transferred from OSIR to ATHX, just to mention that. He obviously looked at the technology. Bummed. Anyway, just a heads up, the mechanism of action in the aftermath of a stroke is similar, though much much faster than UC. Since UC was not good, not expecting much from IS. But there are research documents out there that suggest IS will be good, just like there were supporting documents to suggest UC would be good. Oh well.

PBIO
0.390.00(0.00%)Jul 24 3:44 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.